you are viewing a single comment's thread.
How 'bout a dilutive acquisition of a company that won't add to earnings in this decade.
I am afraid you might be right. The market rewards companies that make money and not the ones that are run like university laboratories or need a constant infusion of cash.
Sentiment: Strong Buy
It looks as if the effect of the Motley Fool and others who mistakenly assume that Pomalidomide competes with Kyrpolis has worn off and the stock can now resume its upward march, presumably with a more informed investor base.